Physician profile
John Peter O'Laughlin
NPI 1356761894
$3,681.54
in general payments reported to CMS, 2019-2025
25 companies · $695 in 2025
The $695 reported for 2025 was more than what a typical Critical Care Medicine (Internal Medicine) provider received nationally (typical 2025 total: $189).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $186 · 2020: $157 · 2021: $256 · 2022: $741 · 2023: $989 · 2024: $658 · 2025: $695.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,341.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,341.43 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abiomed | $686.90 | 2020-2025 | Impella |
| Boehringer Ingelheim Pharmaceuticals, INC. | $586.21 | 2021-2025 | Jardiance |
| Cardiovascular Systems INC. | $318.17 | 2021-2022 | |
| Novartis Pharmaceuticals Corporation | $317.25 | 2022-2025 | |
| Abbott Laboratories | $276.98 | 2022-2024 | Diamondback Peripheral, Diamondback Coronary, Mitraclip |
| Edwards Lifesciences Corporation | $271.91 | 2022-2024 | |
| Janssen Pharmaceuticals, INC | $203.69 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $178.29 | 2021-2025 | Verquvo |
| Pfizer INC. | $130.80 | 2020-2025 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $116.37 | 2022-2025 | Lifevest |
| Medtronic, INC. | $114.98 | 2023 | Micra, Azure Xt Dr Mri Surescan |
| Astrazeneca Pharmaceuticals LP | $68.44 | 2019-2025 | Wainua |
| Sanofi-Aventis U.S. LLC | $60.34 | 2022-2023 | |
| Amgen INC. | $52.89 | 2023-2025 | Repatha |
| Actelion Pharmaceuticals US, INC. | $48.45 | 2023-2024 | Uptravi |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biotronik INC. | $42.73 | 2022-2023 | Orsiro Mission, Nhancer Rx |
| E.R. Squibb & Sons, L.L.C. | $40.51 | 2019 | |
| Csl Behring | $33.58 | 2023 | Kcentra |
| Atricure, INC. | $29.80 | 2023 | |
| Boston Scientific Corporation | $21.86 | 2024 | |
| Acist Medical Systems, INC. | $20.76 | 2024 | |
| Lexicon Pharmaceuticals, INC. | $18.48 | 2024 | |
| Scpharmaceuticals INC. | $18.37 | 2025 | |
| Chiesi USA, INC. | $12.80 | 2023 | Kengreal |
| Penumbra, INC. | $10.98 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John O'Laughlin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.